Posted by Michael Wonder on 03 Mar 2021
Oyster Point Pharma announces FDA acceptance for filing new drug application for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease
2 March 2021 - Prescription Drug User Fee Act target action date is 17 October 2021.
Oyster Point Pharma today announced that the U.S. FDA has accepted its new drug application for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.
